Study on the Combination of Venetoclax and Obinutuzumab for Treating Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of untreated Chronic Lymphocytic Leukemia (CLL).
• Need treatment for CLL according to specific guidelines.
• Have a CIRS score of 6 or less (excluding CLL diagnosis).
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Have adequate blood cell counts and organ function, unless affected by CLL.
• Women of childbearing potential must agree to use effective contraception during treatment and for a specified period after.
• Men must agree to use contraception and refrain from donating sperm during treatment and for a specified period after.

Exclusion Criteria

• Have received any prior treatment for CLL, except for a short course of steroids.
• Have a transformation of CLL to a more aggressive form of cancer.
• Have allergies to any of the study drugs.
• Have a history of other cancers, unless treated and in remission for at least 2 years.
• Have active infections or recent major infections requiring hospitalization.
• Require the use of certain medications that may interact with the study drugs.
• Have significant liver disease or active hepatitis.
• Have a positive test for hepatitis B or C, or HIV.
• Have received live vaccines recently or need them during the study.
• Are pregnant, breastfeeding, or planning to become pregnant during the study.
• Have had recent major surgery.
• Have difficulty swallowing pills or conditions affecting digestion.
• Have known allergies to specific medications used to manage side effects.